setrusumab

Ultragenyx faces class action lawsuit over misleading statements on setrusumab efficacy. Stock crashed 42% after Phase III trials failed. Lead plaintiff deadline: April 6, 2026.

Rosen Law Firm files securities lawsuit against Ultragenyx Pharmaceutical over alleged misleading claims about setrusumab's effectiveness; April 6 deadline for investors with $100K+ losses.

Class action filed against $UGXY alleging misleading statements about Phase III Orbit study for rare bone disease treatment. Investors may recover losses from August 2023 forward.

Ultragenyx faces securities fraud lawsuit after setrusumab Phase 3 failure triggered 42% stock decline. Lead plaintiff applications due April 6, 2026.

Pomerantz Law Firm files securities fraud lawsuit against $MREO after failed Phase 3 trials tank stock 87.7%. Lead Plaintiff deadline: April 6, 2026.

Portnoy Law Firm sues Ultragenyx on behalf of investors over alleged misstatements regarding Phase III Orbit study methodology and efficacy claims for setrusumab.

Rosen Law Firm seeks lead plaintiffs in securities class action against $RARE over alleged misleading statements regarding setrusumab's efficacy in treating osteogenesis imperfecta.

Ultragenyx Pharmaceutical faces securities fraud lawsuit alleging misrepresentations of setrusumab trial results and inadequate risk disclosures to investors.

Ultragenyx stock crashes 42% after disclosing failed Phase 3 trial for setrusumab; investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications in class action lawsuit.

Ultragenyx faces class action alleging misrepresentation of setrusumab trial data using improper Phase II benchmarks. Investors from August 2023–December 2025 may be eligible to join the suit.

Ultragenyx ($RARE) faces class action lawsuit over failed setrusumab Phase 3 trials, with stock down 42%. Investors have until April 6, 2026 to seek lead plaintiff status.

Class action lawsuit filed against Ultragenyx Pharmaceutical alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta treatment based on flawed trial comparisons.

Rosen Law Firm urges MREO investors to act before April 6, 2026 deadline in securities class action alleging misleading clinical trial statements.

Rosen Law Firm notifies $RARE investors of securities class action alleging materially false statements about setrusumab efficacy in Phase III trials, with April 6, 2026 lead plaintiff deadline.

Securities class action filed against RARE over alleged false statements regarding Phase III clinical trials for setrusumab. Claim deadline April 6, 2026.

Rosen Law Firm files securities class action against Ultragenyx Pharmaceutical ($RARE) alleging false statements about setrusumab efficacy in clinical trials.

Ultragenyx faces securities lawsuit after setrusumab Phase 3 trial failure. Stock fell 42%. Investors must apply for class action lead plaintiff status by April 6, 2026.

Securities class action filed against $RARE for allegedly misrepresenting setrusumab efficacy data. Investors may claim damages; lead plaintiff deadline April 6, 2026.

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.